CytoDyn Inc (OTCPK:CYDY)
$ 0.1169 -0.000485 (-0.41%) Market Cap: 142.60 Mil Enterprise Value: 146.84 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 36/100

Cytodyn Inc At This Drug is Now a Leading Contender to Treat COVID-19 Transcript

Apr 27, 2020 / NTS GMT
Release Date Price: $3.73 (+17.30%)
James West
Red Dog Farm - Moderator

Joining me now is Nader Pourhassan. He's the CEO OF CytoDyne Inc, trading on the OTC under symbol, CYDY. Nader, welcome.

Nader Pourhassan
CytoDyn, Inc. - President & CEO

Thank you for having me. Thank you.

Questions & Answers

James West
Red Dog Farm - Moderator

Nader, we're very interested to hear about your late stage leronlimab product, PRO 140, that is being explored for therapeutic indications associated with the COVID-19 virus. Can you tell us all about it, please?

Nader Pourhassan
CytoDyn, Inc. - President & CEO

So, we started with this product to develop it for HIV and when we were successful with our Phase 1, 2, and 3, we hit our primary endpoint and when FDA looked at it, it said you ready for your final application for final approval. [With] submitted one-third, FDA granted us rolling review. They had already given us fast track designation. So, two more section needs to be submitted before the approval

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot